RE: News/trialsI just noticed this on TheStreet.com
On a related note, positive clinical data for a urine-based prostate cancer diagnostic test from
Gen-Probe(GPRO) has been singled out for special notice by the American Society of Clinical Oncology at its Genitourinary Cancer Symposium.
(I wanted to add that these websites are not going to waste their time discussing and looking at a company and their new tests unless they know that it will make a financial impact.)
Whats missing from all the stories is Diagnocure's name.
Once the share price starts to move, we will see a number the the ask orders get pulled quickly and I expect a +20% move.
Investors want in but they want those who are not following the story to dump the shares in their laps